Rameda

(Acq. 2011)

In January 2011, Compass Capital led a consortium to acquire 100% of Rameda, with the vision of establishing the Company as a leader in the industry. The strategy was clearly defined along three distinct pillars:

Creating a sustainable platform by strengthening management capabilities and streamlining the delivery cycle, while focusing on the existing product portfolio.

Upgrading and creating a state of the art facility that is in compliance with latest GMP requirements and adding production lines in new areas of production, all while further automating the production process Leveraging management and R&D expertise to register leading molecules in promising therapeutic areas that would lead the future development of the company.

Compass Capital was successful in bringing on board a new management team with years of managerial experience in multinational firms across the entire asset conversion cycle. The new Management Team was able to work alongside Compass Capital and develop exceptional results across all areas of the business.

Rameda’s plant is situated in the heart of the 6th October industrial zone with a total land area of 41,417 m2 and a total built up area of 32,437 m2. The buildings were designed by V-Konsult, a German engineering company, with the vision of creating the pharmaceutical hub for the region. The construction of the facilities was carried out by the British construction company, British Carter Construction Ltd., which is a specialist developer of healthcare properties in the private sector.

In 2011, post-acquisition of Rameda, the management collaborated with M+W Process Industries GmbH (a global engineering and construction company offering complete process and facilities solutions for pharmaceutical industries) to redesign all production areas in order to incorporate the latest GMP manufacturing requirement and bring the facility at par with the latest technology known in the sector.

Rameda’s plant is comprised of 3 fully integrated standalone factories:
The first factory consists of the following production lines; Sterile Eye / Ear, Solid Dosage, Liquids / Semi-Liquids, Water for Injection and Veterinary Products.
The second factory consists of both sterile and non-sterile cephalosporin and
The third factory consists of a non-sterile penicillin production area.

Rameda's Values

A Broad Portfolio of High Quality Medications
In an attempt to go beyond traditional generic products, they constantly strive to widen their portfolio of medicines to cover a meaningful range of therapeutic areas. Rameda offers a wide range of molecules that cater to a road range of therapeutic areas. Their product lines include:
  • Gastro-Intestinal Tract
  • Ophthalmology (Sterile)
  • Anti-infective
  • Central Nervous System
  • Rig positioning
  • Analgesics
  • Respiratory
  • Cardio-Vascular System
  • Anti-diabetic
  • Vitamins
The Patient
The patient is at the center of their existence. They provide a broad portfolio of medicines that make a real difference in patient healthcare. The generic medicines contain the same active substances as reference medicines and are as effective as the brand name versions, all at an affordable price.
Selling Value, Not Products
Quality is the ultimate value with which they serve their customers. Their manufacturing plant adheres to international standards, which ensures that they can deliver effective and safe medications.
Accessing Everyone
The extensive portfolio of medications that they have guarantees making important medications easily accessible to over 95% of Egypt’s population. It is their commitment to ensure that high quality medications are always at the reach of every patient

Gallery

Contact Us

8 Geziret El Arab Street (23rd Floor), Mohandessin, Giza, Egypt
(+202) 2526 9866
(+202) 2527 7111
(+202) 2526 9864
(+202) 2527 7222